News & Events

Durham, NC (November 05, 2009) -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced today the launch of Clinical Innovations, a new continuing education program for clinical laboratory professionals that consists of courses on timely women’s health diagnostics and laboratory management issues developed and taught by leading clinicians and laboratory experts.

“Clinical laboratory professionals are increasingly challenged to keep up with trends and issues in the laboratory, as well as new technologies and processes, while balancing growing workloads,” said Wayne Brinster, Vice President and General Manager, Women’s Health and Cancer, BD Diagnostics. “Clinical Innovations is designed to provide them with a high-quality and cost-efficient way to stay current on new developments and meet their continuing education requirements.”

Clinical Innovations will consist of modules which will be updated quarterly and presented via DVD. After reviewing the DVD, laboratory personnel can visit a web portal to take a test. Upon successful completion of the test, participants will receive an accredited continuing education unit (CEU) certificate from the American Society for Clinical Laboratory Science’s P.A.C.E. ® (Professional Acknowledgement for Continuing Education) Program.

Initially scheduled program courses are:

• November 2009 – Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) Diagnosis: Confirmatory Testing and New Guidelines from the U.S. Centers for Disease Control and Prevention
  
  
• January 2010 – Gaining Efficiency in the Molecular Diagnostics Laboratory via LEAN Management
  
  
• March 2010 – Clinical Value of DNA-Based Vaginitis Testing

The program tools will be disseminated by BD associates directly to clinical laboratories.

BD Diagnostics focuses on women’s health and cancer by delivering high-quality, productivity-enhancing molecular diagnostics solutions for major women’s health conditions to clinical laboratories worldwide. Its diagnostic instrument systems and assays are used by leading laboratories for the detection and screening of chlamydia, gonorrhea, and vaginitis, as well as cervical cancer. The business is also actively developing tests for herpes simplex virus (HSV-1 and HSV-2) and human papillomavirus (HPV), as well as for ovarian and breast cancer biomarkers.

About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

###